Navigation Links
Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
Date:3/14/2012

COLUMBIA, Md., March 14, 2012 /PRNewswire/ -- The PML Consortium, an association of pharmaceutical and biotechnology companies, has recently selected the Labmatrix and Qiagram software environments from BioFortis to share and manage data relating to biospecimens in a collaborative effort to study a serious adverse event.

Progressive multifocal leukoencephalopathy (PML) is an often-fatal disease caused by the JC virus in immunocompromised patients. PML has been identified as a known side effect to certain immunosuppressive drugs. Several pharmaceutical and biotechnology companies have established the PML Consortium in order to pool study resources together, so they can derive insights that otherwise might not be gained from separate, individual studies. Current members of the PML Consortium include Biogen Idec, Bristol-Myers Squibb, Elan, Pfizer, and Roche.

Through the web-accessible Labmatrix and Qiagram collaborative software environments, global PML Consortium members can 1). centrally manage de-identified or anonymized patient clinical profiles and biospecimen information in the virtual sample bank, 2). explore available biospecimens in the virtual sample bank and related data using complex, ad hoc criteria, 3). request, approve, and track transfers of biospecimens in the virtual sample bank, and  4). log user interactions and virtual sample bank inventory history for usage transparency, information security, and accountability.

"This application will enable us to store clinical data and sample data collected by the Consortium, and enable research to be carried out in an innovative collaborative effort and thorough scientific approach into PML and its causes," states Sophie Banzet, M.D., Chair of the PML Consortium Board of Directors.

"With the complementary capabilities of a transactional database for managing daily scientific operations, and a graphical data exploration engine for posing complex questions," states BioFortis CEO Jian Wang, Ph.D., "our software environment is an informatics one-stop-shop for the PML Consortium researchers and collaborators."

About BioFortis, Inc.

BioFortis, Inc. provides enterprise software solutions within several key application areas including translational research, biobanking, biomarker discovery and clinical research. With the ability to centralize life sciences data sets in a tightly-linked, highly-annotated, and user-friendly manner, our solutions help customers to standardize on best practices in research data management within the biopharmaceutical industry, academia and government research institutions. BioFortis' website address is www.BioFortis.com

Labmatrix and Qiagram are registered marks of BioFortis, Inc.


'/>"/>
SOURCE BioFortis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
2. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
3. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
4. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
5. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
6. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
7. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
8. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
9. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
10. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
11. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):